Therapeutic effect of fibroblast growth factor 21 on NAFLD in MSG-IR mice and its mechanism

Yaoxue Xuebao

Volumn 48, Issue 12, 2013, Pages 1778-1784

  Zhu, Sheng Long ^a   Zhang, Zhen Yu ^a   Ren, Gui Ping ^a   Ye, Xian Long ^a   Ma, Lei ^a   Yu, Dan ^a   Han, Miao Miao ^a   Zhao, Jing Zhuang ^b   Zhang, Tian Yuan ^a   Li, De Shan ^a  

^a NORTHEAST AGRICULTURAL UNIVERSITY   (China)

^b SOUTH CHINA SEA FISHERIES RESEARCH INSTITUTE   (China)

Author keywords

Fibroblast growth factor 21; Insulin resistance; MSG; Non alcoholic fatty liver disease

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 21; GLUTAMATE SODIUM;

ANIMAL; BODY WEIGHT; CHEMICALLY INDUCED; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; DYSLIPIDEMIA; ENERGY METABOLISM; FATTY LIVER; FEMALE; INSULIN RESISTANCE; LIPOLYSIS; LIVER; MALE; METABOLISM; MOUSE; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ANIMALS; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; ENERGY METABOLISM; FATTY LIVER; FEMALE; FIBROBLAST GROWTH FACTORS; INSULIN RESISTANCE; LIPOLYSIS; LIVER; MALE; MICE; NON-ALCOHOLIC FATTY LIVER DISEASE; SODIUM GLUTAMATE;

EID: 84894377590     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Kallwitz ER, McLachlan A, Cotier SJ. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease [J]. World J Gastroenterol, 2008, 14: 22-28. (Pubitemid 351314322)
2. Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome [J], Am J Med Sci, 2005,330: 326 -335.
3. Zhang DY, Liu ZY, Choi CS, et al. Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance [J]. Proc Natl Acad Sci USA, 2007, 104: 17075-17080.
4. Nishimura T, Nakatake Y, Konishi M, et al. Identification of a novel FGF, FGF-21, preferentially expressed in the liver [J], Biochim Biophys Acta, 2000, 1492:203 -206.
5. Kharitonenkov A, Wroblewski VJ, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21 [J], Endocrinology, 2007, 148: 774-781. (Pubitemid 46143178)
6. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator [J], Clin Invest, 2005, 115: 1627-1635. (Pubitemid 40814671)
7. Inagaki T, Dutchak P, Zhao GX, et al. Endocrine regulation of the fasting response by PPARa-mediated induction of fibroblast growth factor 21 [J], Cell Metab, 2007, 5:415 425
8. Watanabe M, Shimada T, Iiduka S, et al. Preventive effects of Salada reticulata on non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) in monosodium glutamate treated mice [J]. J Tradit Med, 2011, 28: 73 -82.
9. Sun GP, Ye XL, Ren GP, et al. Fibroblast growth factor-21 mediates hepatic glucose metabolism of type 1 diabetes model and its mechanism [J], Prog Biochem Biophys, 2011, 38: 953-960.
10. Sun SJ, Shen ZF, Chen YT, et al. Effects of conjugated linoleic acid on obese MSG mice with insulin resistance [J]. Acta Pharm Sin, 2003, 38: 904-907.
11. Liu SN, Liu Q, Shen ZF. A preliminary study on the mechanism of impaired beta cell function in monosodium glutamate obese rat with insulin resistance [J]. Acta Pharm Sin 2008,43: 1106-1111.
12. Xu XZ, Zhao CX, Wang LY, et al. Increased CYP2J3 expression reduces insulin resistance in fructose-treated rats and db/db mice [J], Diabetes, 2010, 59: 997-1005.
13. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study [J], Hepatology, 2005,42:44 -52.
14. Duvnjak M, Lerotió I, Barsić N, et al. Pathogenesis and management issues for non-alcoholic fatty liver disease [J]. World J Gastroenterol, 2007, 13:4539-4550. (Pubitemid 47455230)
15. Sobhonslidsuk A, Jongjirasiri S, Thakkinstian A, et al. Visceral fat and insulin resistance as predictors of non-alcoholic steatohepatitis [J], World J Gastroenterol, 2007, 13: 3614-3618.
16. Xu J, Lloyd DJ, Hale C, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice [J], Diabetes, 2009, 58: 250-259.